Mink Therapeutics reported a complete and durable remission in a testicular cancer patient treated with its allogeneic invariant natural killer T-cell therapy Agent-797 combined with nivolumab. Published in Nature’s Oncogene, the case involved a 49-year-old male with germ cell neoplasm who showed no evidence of disease two years following a single infusion. The dramatic clinical response propelled Mink’s stock up by 730%, highlighting the potential of off-the-shelf immune cell therapies to achieve meaningful cancer control.